Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

June 2023

Inibidores de JAK e o risco de malignidades: Uma meta-análise com as indicações de tratamento

Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049

Patel V,

Adas MA,

Ng KKH,

Cope AP,

The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.

Keywords:

March 2023

Segurança de Baricitinib para Eventos de Interesse Especial em Populações em Risco: Uma análise de dados de ensaios randomizados em indicações reumatológicas e dermatológicas

Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w

Taylor PC,

Bieber T,

Alten R,

Witte T,

Issa M,

Grond S,

Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.

Keywords:

February 2023

Infecções Oportunistas Associadas com o Tratamento com Inibidores de Janus Quinase em Artrite Reumatoide: Uma Revisão Estruturada da Literatura

Semin Arthritis Rheum. 2023;58:152120

Desai S,

Barry J,

Strengholt S,

Galloway J

Structured literature review shows a varied incidence of opportunistic infections (OIs) among RA patients exposed to JAK inhibitors.